P. Kaufman

Jong-Hyeon Jeong, Peter A Kaufman, Norman Wolmark, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2-positive breast cancer: the story goes on.

P. Kaufman, M. Chamberlin, 2014, Oncology.

The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831.

Y. Asmann, E. Perez, E. Thompson, 2013 .

PD05-03: Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831.

S. Martino, G. Sledge, L. Harris, 2011 .

Nuclear expression of the 50- and 65-kD Rel-related subunits of nuclear factor-kappa B is differentially regulated in human monocytic cells.

W. Greene, P. Kaufman, J. Weinberg, 1992, The Journal of clinical investigation.

P. Neven, G. Sledge, E. Grischke, 2020, The oncologist.

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer

P. Neven, G. Sledge, S. Johnston, 2021, Clinical Cancer Research.

Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

J. Wanders, C. Twelves, A. Awada, 2012 .

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

M. Olivo, C. Twelves, A. Awada, 2016, Breast cancer : basic and clinical research.

Cancer Care in the Wake of a Cyberattack: How to Prepare and What to Expect

P. Kaufman, C. Holmes, T. Plante, 2021, JCO Oncology Practice.

A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer

E. Perez, A. Jaffe, S. Martino, 2007 .

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

P. Fasching, Sung-Bae Kim, W. Gradishar, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective

B. Pogue, K. Paulsen, A. Tosteson, 2009, Breast Cancer Research and Treatment.

Pre-treatment breast MRI and diffuse optical spectroscopic tomography can predict complete response to neoadjuvant chemotherapy

B. Pogue, K. Paulsen, Shudong Jiang, 2016 .

Pre-treatment total hemoglobin in breast cancer is a predictor for complete response to neoadjuvant chemotherapy

B. Pogue, K. Paulsen, Shudong Jiang, 2014 .

C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Peter A Kaufman, Lyndsay N Harris, James N Ingle, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bispecific Antibody MDX-210 for Treatment of Advanced Ovarian and Breast Cancer.

P. Wallace, M. Ernstoff, P. Kaufman, 2001, Methods in molecular medicine.

The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer

P. Wallace, M. Waugh, J. Fisher, 2002, Cancer Chemotherapy and Pharmacology.

The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831

Y. Asmann, E. Perez, E. Thompson, 2015, Breast Cancer Research.

Plasma DNA as a “liquid biopsy” incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer

J. Gui, J. Gemery, P. Kaufman, 2020, Breast Cancer Research and Treatment.

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.

J. Fisher, P. Kaufman, R. Graziano, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

V. Karantza, M. Olivo, P. Kaufman, 2017 .

P. Neven, G. Sledge, E. Grischke, 2019, The oncologist.

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

P. Neven, G. Sledge, S. Johnston, 2019, JAMA oncology.

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

P. Neven, G. Sledge, X. Pivot, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhancing global access to cancer medicines

J. Tabernero, F. Cardoso, G. Curigliano, 2020, CA: a cancer journal for clinicians.

Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival

John W. Adams, L. Bosserman, D. Yardley, 2015, Breast Cancer Research.

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

M. Caligiuri, C. Shapiro, G. Fleming, 2009, Breast Cancer Research and Treatment.

Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment

Stefan A. Carp, Brian Pogue, Bruce J. Tromberg, 2018, Journal of biomedical optics.

The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation

W. Greene, M. Hannink, W. Walker, 1992, Journal of virology.

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

E. Perez, S. Martino, G. Sledge, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu.

J. Fisher, M. Ernstoff, P. Kaufman, 1995, Journal of hematotherapy.

Cognitive function in breast cancer patients prior to adjuvant treatment

Andrew J. Saykin, Peter A. Kaufman, Brenna C. McDonald, 2008, Breast Cancer Research and Treatment.

Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs

H. Rugo, S. Swain, M. Cobleigh, 2019, Clinical Cancer Research.

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

J. Robertson, H. Kennecke, P. Kaufman, 2013, The Lancet. Oncology.

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

V. Karantza, D. Patt, R. O'Regan, 2021, Clinical Cancer Research.

The impact of sharing results of a randomized breast cancer clinical trial with study participants

E. Winer, D. Lake, R. Gelman, 2009, Breast Cancer Research and Treatment.

Phase I Pilot Trial of the Bispecific Antibody MDXH210 (anti-Fc&ggr;RI X anti–HER-2/neu) in Patients Whose Prostate Cancer Overexpresses HER-2/neu

A. Schned, M. Ernstoff, P. Kaufman, 2001, Journal of immunotherapy.

P. Neven, G. Sledge, P. Kaufman, 2018 .

Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.

D. Berry, E. Winer, C. Hudis, 2008, Cancer treatment reviews.

Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma

S. Conzen, P. Kaufman, L. Mott, 1996, Cancer.

Autologous bone marrow transplantation and factor xii, factor vii, and protein c deficiencies report of a new association and its possible relationship to endothelial cell injury

P. Kaufman, C. Greenberg, R. Jones, 1990, Cancer.

Rex transregulation of human T-cell leukemia virus type II gene expression

W. Greene, P. Kaufman, S. Hanly, 1991, Journal of virology.

Feasibility study of a randomized controlled trial of a telephone‐delivered problem‐solving–occupational therapy intervention to reduce participation restrictions in rural breast cancer survivors undergoing chemotherapy

M. Hegel, T. Ahles, P. Kaufman, 2011, Psycho-oncology.

Fast 3-D Tomographic Microwave Imaging for Breast Cancer Detection

Paul M. Meaney, Keith D. Paulsen, Tomasz M. Grzegorczyk, 2012, IEEE Transactions on Medical Imaging.

A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.

K. Yonemori, M. Beeram, S. Estrem, 2022, Journal of Clinical Oncology.

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

Peter A Kaufman, K. Bloom, H. Rugo, 2014, Cancer.

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

H. Rugo, S. Swain, D. Tripathy, 2014, BMC Cancer.

Y. Asmann, E. Perez, E. Thompson, 2015, Breast Cancer Research.

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer

H. Rugo, D. Tripathy, D. Yardley, 2014, Breast Cancer Research and Treatment.

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER

H. Rugo, J. Magidson, D. Tripathy, 2014, British Journal of Cancer.

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study

H. Rugo, D. Tripathy, D. Yardley, 2012, Breast Cancer Research and Treatment.

First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.

H. Rugo, D. Tripathy, D. Yardley, 2013, The oncologist.

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry

H. Rugo, S. Swain, M. Cobleigh, 2019, The oncologist.

Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment

P Jack Hoopes, Alicia A Petryk, Andrew J Giustini, 2013, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve.

Andrew J Saykin, Yuelin Li, Peter A Kaufman, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo.

P. Wallace, A. Givan, M. Waugh, 2001, Journal of immunological methods.

Randomized double-blind phase 2 study evaluating sameday vs next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (tac) in women with early stage and advanced breast cancer

P. Kaufman, L. Dean, S. Shahin, 2004 .

A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).

V. Karantza, D. Patt, R. O'Regan, 2020 .

Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.

A. Saven, H. Burris, P. Kaufman, 2010, Journal of oncology practice.

A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.

Sung-Bae Kim, K. Yonemori, M. Beeram, 2021 .

Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2‐Positive Locally Recurrent or Metastatic Breast Cancer

H. Wildiers, A. Stopeck, G. Jerusalem, 2019, Clinical breast cancer.

Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer

A. Buzdar, B. Overmoyer, P. Kaufman, 2005 .

Effect of neuromuscular electrical stimulation on skeletal muscle size and function in patients with breast cancer receiving chemotherapy.

P. Kaufman, M. Wood, T. Tourville, 2020, Journal of applied physiology.

Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial.

E. Perez, S. Martino, S. Dakhil, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

John W. Adams, L. Bosserman, D. Yardley, 2015, Breast Cancer Research.

Development and Initial Evaluation of a Telephone-Delivered, Behavioral Activation, and Problem-Solving Treatment Program to Address Functional Goals of Breast Cancer Survivors

M. Hegel, T. Ahles, P. Kaufman, 2015, Journal of psychosocial oncology.

Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

E. Perez, S. Martino, T. Pisansky, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer

P. Mainwaring, B. Koczwara, P. Kaufman, 2012, Breast Cancer Research and Treatment.

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

E. Winer, B. Gersh, E. Perez, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

E. Perez, S. Martino, G. Sledge, 2013, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine Impact of c-MYC Protein Expression on Outcome of Patients withEarly-StageHER 2 þ BreastCancerTreatedwithAdjuvant Trastuzumab NCCTG ( Alliance ) N 9831

E. Perez, S. Martino, G. Sledge, 2013 .

Health Through Activity: Initial Evaluation of an In-Home Intervention for Older Adults With Cancer.

M. Hegel, S. Bartels, M. Bruce, 2019, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

E. Perez, M. Olivo, C. Twelves, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study.

N. Dreyer, J. Sloan, C. Cleeland, 2014, Breast.

Comparison of iron oxide nanoparticle and microwave hyperthermia alone or combined with cisplatinum in murine breast tumors

P Jack Hoopes, Alicia A Petryk, Andrew J Giustini, 2011, BiOS.

A dual-reporter fluorescent imaging approach can be used to estimate sentinel lymph node tumor burden

Ramesh Govindan, Jason R. Gunn, Brian W. Pogue, 2013, Photonics West - Biomedical Optics.

Long-term enteral nutrition support in a pregnant patient following head trauma.

K. Kudsk, P. Kaufman, R. Brown, 1989, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.

B. Gersh, E. Perez, A. Jaffe, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy Monitoring With EIS: Early Findings

K. Paulsen, A. Hartov, P. Kaufman, 2007 .

Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine

P. Kaufman, R. Hauser, Debanjana Chatterjee, 2020, Breast Cancer Research and Treatment.

Abstract P3-07-14: Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: Early results from the systemic therapies for HER2-positive metastatic breast cancer registry study

H. Rugo, S. Swain, M. Cobleigh, 2015 .

Microwave tomography in the context of complex breast cancer imaging

Shireen D. Geimer, Paul M. Meaney, Keith D. Paulsen, 2010, 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology.

212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)

P. Kaufman, K. Petráková, G. Paux, 2022, Annals of Oncology.

Alliance A071701: Genomically guided treatment trial in brain metastases.

S. Carter, P. Brown, A. Iafrate, 2020 .

Abstract PS10-12: Integrated safety summary of single agent and combination margetuximab in phase 1, 2, and 3 studies of HER2-positive advanced cancers and metastatic breast cancer (MBC)

Sung-Bae Kim, W. Gradishar, E. Rock, 2021 .

Radiotherapy concurrent with trastuzumab is well tolerated in the adjuvant treatment of women with HER2-positive breast cancer: cardiac safety data from the NCCTG N9831 study

E. Perez, S. Martino, T. Pisansky, 2006 .

Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial.

E. Perez, S. Martino, G. Sledge, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831.

E. Perez, S. Martino, G. Sledge, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P1-12-08: Quality of Life in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes who Received Eribulin Mesylate or Capecitabine in a Phase III, Open-label, Randomized Study

J. Wanders, M. Olivo, C. Twelves, 2012 .

“New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

E. Perez, J. O’Shaughnessy, M. Olivo, 2015, Breast Cancer Research.

A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses.

E. Perez, J. Wanders, M. Olivo, 2013 .

Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study.

E. Perez, J. Wanders, M. Olivo, 2013 .

Real-Time Electrical Impedance Variations in Women With and Without Breast Cancer

Keith D. Paulsen, Steven P. Poplack, Ryan J. Halter, 2015, IEEE Transactions on Medical Imaging.

Reply to N. Magné et al

E. Perez, S. Martino, T. Pisansky, 2009 .

MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer

P. Neven, G. Sledge, X. Pivot, 2019, Annals of Oncology.

Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu.

P. Wallace, M. Waugh, J. Fisher, 2001, Journal of immunological methods.

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

H. Rugo, S. Swain, D. Tripathy, 2014, BMC Cancer.

Goal Attainment and Goal Adjustment of Older Adults During Person‐Directed Cancer Rehabilitation

M. Hegel, S. Bartels, M. Bruce, 2018, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

H. Iwata, N. Ternès, M. Campone, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Collagen quantification in breast tissue using a 12-wavelength near infrared spectral tomography (NIRST) system.

Brian W Pogue, Keith D Paulsen, Shudong Jiang, 2017, Biomedical optics express.

MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy

P. Neven, G. Sledge, X. Pivot, 2017 .

Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2+BC): Results from the NCCTG adjuvant Intergroup trial N9831

E. Perez, S. Martino, N. Davidson, 2008 .

P2-12-02: Correlation between BMI and Clinical Outcome of Patients with Early Stage HER2+ Breast Cancer from the N9831 Clinical Trial.

S. Martino, K. Ballman, N. Davidson, 2011 .

Multicenter, non-randomized phase II study with RPR109881 in taxane-exposed metastatic breast cancer (MBC) patients (pts): Final results

G. Romieu, V. Diéras, P. Kaufman, 2005 .